Concurrent chemoradiotherapy for advanced pancreatic cancer: 1,000 mg/m2 Gemcitabine can be administered using limited-field radiotherapy

Strahlentherapie und Onkologie

Volumn 183, Issue 6, 2007, Pages 301-306

  Yamazaki, Hideya ^a,b   Nishiyama, Kinji ^a   Koizumi, Masahiko ^a   Tanaka, Eiichi ^a   Ioka, Tatsuya ^a   Uehara, Hiroyuki ^a   Iishi, Hiroyasu ^a   Nakaizumi, Akihiko ^a   Ohigashi, Hiroaki ^a   Ishikawa, Osamu ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b OSAKA NATIONAL HOSPITAL   (Japan)

Author keywords

3D CRT; Gemcitabine; Limited field radiotherapy; Pancreatic cancer

Indexed keywords

GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; INOPERABLE CANCER; INTRAOPERATIVE RADIOTHERAPY; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; PANCREAS CANCER; PEROPERATIVE CARE; RADIATION DOSE; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; THREE DIMENSIONAL IMAGING; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; RADIATION INJURIES; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; SURVIVAL RATE;

EID: 34347221166     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-007-1641-1     Document Type: Article

References (31)

1. Abbruzzese JL. New applications of gemcitabine and future directions in the management of pancreatic cancer. Cancer 2002;95:Suppl:941-5.
2. Allen AM, Zalupski MM, Robertson JM, et al. Adjuvant therapy in pancreatic cancer: phase I trial of radiation dose escalation with concurrent full-dose gemcitabine. Int J Radiat Oncol Biol Phys 2004;59:1461-7.
3. Blackstock AW, Bernard SA, Richards F, et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 1999;17:2208-12.
4. Brunner TB, Hahn SM, McKenna WG, et al. Radiation sensitization by inhibition of activated Ras. Strahlenther Onkol 2004;180:731-40.
5. Brunner TB, Tinkl D, Grabenbauer GG, et al. Maintenance chemotherapy after chemoradiation improves survival of patients with locally advanced pancreatic carcinoma: a retrospective analysis of prospectively recruited patients. Strahlenther Onkol 2006;182:210-5.
6. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
7. Catalano G, Jereczek-Fossa BA, De Pas T, et al. Three-times-daily radiotherapy with induction chemotherapy in locally advanced non-small cell lung cancer. Feasibility and toxicity study. Strahlenther Onkol 2005; 181:363-71.
8. Crane CH, Abbruzzese JL, Evans DB, et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 2002;52:1293-302.
9. De Lange SM, van Groeningen CJ, Meijer OW, et al. Gemcitabine- radiotherapy in patients with locally advanced pancreatic cancer. Eur J Cancer 2002;38:1212-7.
10. Epelbaum R, Rosenblatt E, Nasrallah S, et al. Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. J Surg Oncol 2002;81:138-43.
11. Gagel B, Piroth M, Pinkawa M, et al. Gemcitabine concurrent with thoracic radiotherapy after induction chemotherapy with gemcitabine/vinorelbine in locally advanced non-small cell lunger cancer. A phase I study. Strahlenther Onkol 2006;182:2263-9.
12. Gastrointestinal Tumor Study Group. Radiation therapy combined with adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Cancer 1985;56:2563-8.
13. Ikeda M, Okada S, Tokuuye K, et al. A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer 2002;86:1551-4.
14. Ioka T, Iishi H, Tanaka S, et al. A phase I trial of radiation (GEM)(RT) dose escalation with concurrent full dose gemcitabine (GEM) for unresectable locally advanced pancreastic cancer. Proc Am Soc Clin Oncol 2003;22:376 (abstract).
15. Ishii H, Okada S, Tokuuye K, et al. Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 1997;79:1516-20.
16. Ito Y, Okusaka T, Kagami Y, et al. Evaluation of acute intestinal toxicity on relation to the volume of irradiated small bowel in patients treated with concurrent weekly gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2003;57:Suppl:383-4.
17. Kawakami H, Uno T, Isobe K, et al. Toxicity and effects of involved-field irradiation with concurrent cisplatin for unresectable carcinoma of the pancreas. Int J Radiat Oncol Biol Phys 2005;14:1357-62.
18. Lawrence TS, Chang EY, Hahn TM, et al. Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine. Int J Radiat Oncol Biol Phys 1996;34:867-72.
19. Li CP, Chao Y, Chi KH, et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 2003;57:98-104.
20. Milas L, Fujii T, Hunter N, et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 1999;59:107-14.
21. McGinn CJ, Zalupski MM. Radiation therapy with once-weekly gemcitabine in pancreatic cancer: current status of clinical trials. Int J Radiat Oncol Biol Phys 2003;56:Suppl:10-5.
22. Morganti AG, Forni F, Macchia G, et al. Chemoradiation of unresectable pancreatic carcinoma: impact of pretreatment hemoglobin level on patterns of failure. Strahlenther Onkol 2003;179:87-92.
23. Ohigashi H, Ishikawa O, Eguchi H, et al. Feasibility and efficacy of combination therapy with preoperative and postoperative chemoradiation, extended pancreatectomy, and postoperative liver perfusion chemotherapy for locally advanced cancers of the pancreatic head. Ann Surg Oncol 2005;12:629-36.
24. Okusaka T, Ito Y, Ueno H, et al. Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br J Cancer 2004;91:673-7.
25. Oya N. Chemoradiotherapy for pancreatic cancer: current status and perspectives. Int J Clin Oncol 2004;9:451-7.
26. Poggi MM, Kroog GS, Russo A, et al. Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2002;54:670-6.
27. Semrau S, Gerber B, Reimer T, et al. Concurrent radiotherapy and taxane chemotherapy in patients with locoregional recurrence of breast cancer. A retrospective analysis. Strahlenther Onkol 2006;182:596-603.
28. Storniolo AM, Enas NH, Brown CA, et al. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 1999;85:1261-8.
29. Tokuuye K, Sumi M, Kagami Y, et al. Small-field radiotherapy in combination with concomitant chemotherapy for locally advanced pancreatic carcinoma. Radiother Oncol 2003;67:327-30.
30. Weiss C, Grabenbauer, Sauer R, et al. Significant increase in residual DNA damage as a possible mechanism of radiosensitization by gemcitabine. Strahlenther Onkol 2003;179:93-8.
31. Wilkowski R, Thoma M, Heinemann V, et al. Radiochemotherapy with gemcitabine and cisplatin in pancreatic cancer - feasible and effective. Strahlenther Onkol 2003;179:78-86.